These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33859749)

  • 21. A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
    Larue RT; Van De Voorde L; Berbée M; van Elmpt WJ; Dubois LJ; Panth KM; Peeters SG; Claessens A; Schreurs WM; Nap M; Warmerdam FA; Erdkamp FL; Sosef MN; Lambin P
    BMC Cancer; 2016 Aug; 16():644. PubMed ID: 27535748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity.
    Spiegelberg L; van Hoof SJ; Biemans R; Lieuwes NG; Marcus D; Niemans R; Theys J; Yaromina A; Lambin P; Verhaegen F; Dubois LJ
    Radiother Oncol; 2019 Dec; 141():247-255. PubMed ID: 31431383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer.
    Haynes J; McKee TD; Haller A; Wang Y; Leung C; Gendoo DMA; Lima-Fernandes E; Kreso A; Wolman R; Szentgyorgyi E; Vines DC; Haibe-Kains B; Wouters BG; Metser U; Jaffray DA; Smith M; O'Brien CA
    Clin Cancer Res; 2018 May; 24(9):2116-2127. PubMed ID: 29476017
    [No Abstract]   [Full Text] [Related]  

  • 24. Antagonism in effectiveness of evofosfamide and doxorubicin through intermolecular electron transfer.
    Anderson RF; Li D; Hunter FW
    Free Radic Biol Med; 2017 Dec; 113():564-570. PubMed ID: 29111232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.
    Portwood S; Lal D; Hsu YC; Vargas R; Johnson MK; Wetzler M; Hart CP; Wang ES
    Clin Cancer Res; 2013 Dec; 19(23):6506-19. PubMed ID: 24088735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma.
    Wang B; Qi FZ; Chen P; Qian LM; Su HS; Wang Y; Wang CH; Hou YX; Zhang Q; Li D; Chen ZS; Zhang SH
    Int J Biol Sci; 2024; 20(5):1634-1651. PubMed ID: 38481819
    [No Abstract]   [Full Text] [Related]  

  • 27. Evofosfamide, a new horizon in the treatment of pancreatic cancer.
    Pourmorteza M; Rahman ZU; Young M
    Anticancer Drugs; 2016 Sep; 27(8):723-5. PubMed ID: 27232101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.
    Liu Q; Sun JD; Wang J; Ahluwalia D; Baker AF; Cranmer LD; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1487-98. PubMed ID: 22382881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.
    Hong CR; Dickson BD; Jaiswal JK; Pruijn FB; Hunter FW; Hay MP; Hicks KO; Wilson WR
    Biochem Pharmacol; 2018 Oct; 156():265-280. PubMed ID: 30134191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy.
    Saggar JK; Tannock IF
    Int J Cancer; 2014 Jun; 134(11):2726-34. PubMed ID: 24338277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging.
    Peeters SG; Zegers CM; Biemans R; Lieuwes NG; van Stiphout RG; Yaromina A; Sun JD; Hart CP; Windhorst AD; van Elmpt W; Dubois LJ; Lambin P
    Clin Cancer Res; 2015 Jul; 21(13):2984-92. PubMed ID: 25805800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma.
    Liapis V; Labrinidis A; Zinonos I; Hay S; Ponomarev V; Panagopoulos V; DeNichilo M; Ingman W; Atkins GJ; Findlay DM; Zannettino ACW; Evdokiou A
    Cancer Lett; 2015 Feb; 357(1):160-169. PubMed ID: 25444931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.
    Hu J; Handisides DR; Van Valckenborgh E; De Raeve H; Menu E; Vande Broek I; Liu Q; Sun JD; Van Camp B; Hart CP; Vanderkerken K
    Blood; 2010 Sep; 116(9):1524-7. PubMed ID: 20530289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
    Chawla SP; Cranmer LD; Van Tine BA; Reed DR; Okuno SH; Butrynski JE; Adkins DR; Hendifar AE; Kroll S; Ganjoo KN
    J Clin Oncol; 2014 Oct; 32(29):3299-306. PubMed ID: 25185097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors.
    Lindsay D; Garvey CM; Mumenthaler SM; Foo J
    PLoS Comput Biol; 2016 Aug; 12(8):e1005077. PubMed ID: 27560187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model.
    Cárdenas-Rodríguez J; Li Y; Galons JP; Cornnell H; Gillies RJ; Pagel MD; Baker AF
    Magn Reson Imaging; 2012 Sep; 30(7):1002-9. PubMed ID: 22554971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer.
    Yoon J; Kang SY; Lee KH; Cheon GJ; Oh DY
    Cancer Res Treat; 2021 Apr; 53(2):471-479. PubMed ID: 33091966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas.
    Yoon C; Lee HJ; Park DJ; Lee YJ; Tap WD; Eisinger-Mathason TS; Hart CP; Choy E; Simon MC; Yoon SS
    Br J Cancer; 2015 Jun; 113(1):46-56. PubMed ID: 26010414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma.
    Constantinidou A; van der Graaf WTA
    Eur J Cancer; 2017 Oct; 84():257-261. PubMed ID: 28841543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
    Guise CP; Mowday AM; Ashoorzadeh A; Yuan R; Lin WH; Wu DH; Smaill JB; Patterson AV; Ding K
    Chin J Cancer; 2014 Feb; 33(2):80-6. PubMed ID: 23845143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.